Esketamine clinical trials: reply to Maju et al.

Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastaldon, C., Papola, D., Ostuzzi, G., Barbui, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Epidemiology in Clinical Psychopharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214734/
https://www.ncbi.nlm.nih.gov/pubmed/32345395
http://dx.doi.org/10.1017/S204579602000027X
_version_ 1783532031732350976
author Gastaldon, C.
Papola, D.
Ostuzzi, G.
Barbui, C.
author_facet Gastaldon, C.
Papola, D.
Ostuzzi, G.
Barbui, C.
author_sort Gastaldon, C.
collection PubMed
description Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
format Online
Article
Text
id pubmed-7214734
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-72147342020-05-18 Esketamine clinical trials: reply to Maju et al. Gastaldon, C. Papola, D. Ostuzzi, G. Barbui, C. Epidemiol Psychiatr Sci Epidemiology in Clinical Psychopharmacology Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval. Cambridge University Press 2020-04-29 /pmc/articles/PMC7214734/ /pubmed/32345395 http://dx.doi.org/10.1017/S204579602000027X Text en © The Author(s) 2020 http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Epidemiology in Clinical Psychopharmacology
Gastaldon, C.
Papola, D.
Ostuzzi, G.
Barbui, C.
Esketamine clinical trials: reply to Maju et al.
title Esketamine clinical trials: reply to Maju et al.
title_full Esketamine clinical trials: reply to Maju et al.
title_fullStr Esketamine clinical trials: reply to Maju et al.
title_full_unstemmed Esketamine clinical trials: reply to Maju et al.
title_short Esketamine clinical trials: reply to Maju et al.
title_sort esketamine clinical trials: reply to maju et al.
topic Epidemiology in Clinical Psychopharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214734/
https://www.ncbi.nlm.nih.gov/pubmed/32345395
http://dx.doi.org/10.1017/S204579602000027X
work_keys_str_mv AT gastaldonc esketamineclinicaltrialsreplytomajuetal
AT papolad esketamineclinicaltrialsreplytomajuetal
AT ostuzzig esketamineclinicaltrialsreplytomajuetal
AT barbuic esketamineclinicaltrialsreplytomajuetal

Ejemplares similares